Monitor for any further C-suite departures or delays in clinical development timelines. The internal absorption of CMO duties suggests continuity, but the lack of a named replacement could signal organizational flux.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $3.82entry
- T+1 · 5mo ago +5.76%α +5.89% · $4.04
- T+5 · 4mo ago +6.81%α +6.20% · $4.08
- T+20 · 4mo ago +5.76%α +6.79% · $4.04
- T+60 · 8w ago −7.33%α −10.15% · $3.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protara Therapeutics disclosed the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., effective June 26, 2026, to pursue other opportunities. His responsibilities will be absorbed by existing clinical leadership, including Carla Beckham, M.D. and Jacqueline Zummo, Ph.D. This is a routine officer departure with no immediate financial or operational impact.
Key Facts
- Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to explore other opportunities.
- Duties will be subsumed by Lead Medical Director Carla Beckham, M.D. under oversight of Chief R&D Officer Jacqueline Zummo, Ph.D.
- No replacement CMO has been named; no compensation or employment agreement details were disclosed.
Financial Impact
No financial impact disclosed.
Risk Factors
- Potential disruption to clinical development programs if the departing CMO was a key driver.
- Further executive departures could signal broader organizational instability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-073184 |
| Document: 0001213900-26-073184-index-headers.html | 0001213900-26-073184 |
| Document: 0001213900-26-073184-index.html | 0001213900-26-073184 |
| Document: 0001213900-26-073184.txt | 0001213900-26-073184 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Viewing Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers